Stock 605116 AURISCO PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Aurisco Pharmaceutical Co.,Ltd.

Equities

605116

CNE1000042S4

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
24.76 CNY +0.49% Intraday chart for Aurisco Pharmaceutical Co.,Ltd. +8.26% -4.11%
Apr. 28 Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
2023 Aurisco Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 6,364 8,830 10,029 10,057 10,057 -
Enterprise Value (EV) 1 6,364 8,830 10,029 10,488 10,057 10,057
P/E ratio 37.8 x 52.4 x 47.5 x 36.4 x 25.8 x 19.5 x
Yield - - - - - -
Capitalization / Revenue 8.82 x 11 x 9.95 x 8.31 x 5.95 x 4.62 x
EV / Revenue 8.82 x 11 x 9.95 x 8.31 x 5.95 x 4.62 x
EV / EBITDA - 37.6 x 32.6 x 25.7 x 19.6 x 15.6 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - 5.86 x 5.98 x 5.33 x 4.57 x 3.95 x
Nbr of stocks (in thousands) 401,000 401,000 406,195 406,195 406,195 -
Reference price 2 15.87 22.02 24.69 24.76 24.76 24.76
Announcement Date 4/19/21 4/29/22 4/14/23 4/28/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 721.4 803.4 1,008 1,263 1,691 2,175
EBITDA 1 - 234.9 307.8 407.4 512 643
EBIT 1 - 193.6 241.3 330.7 450.5 595.5
Operating Margin - 24.1% 23.93% 26.2% 26.64% 27.38%
Earnings before Tax (EBT) 1 - 192 240.8 329.1 450 595
Net income 1 - 168.7 210.9 289.4 389.5 515.4
Net margin - 21% 20.92% 22.92% 23.03% 23.7%
EPS 2 0.4200 0.4200 0.5200 0.7100 0.9600 1.270
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 4/19/21 4/29/22 4/14/23 4/28/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - 11.7% 13.3% 16.1% 17.7% 20.2%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - 3.760 4.130 4.840 5.420 6.280
Cash Flow per Share 2 - 0.5000 0.4100 0.9500 0.8100 1.210
Capex 1 - 250 216 305 200 165
Capex / Sales - 31.12% 21.39% 24.15% 11.83% 7.59%
Announcement Date 4/19/21 4/29/22 4/14/23 4/28/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Aurisco Pharmaceutical Co.,Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
24.76 CNY
Average target price
31 CNY
Spread / Average Target
+25.20%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
AURISCO PHARMACEUTICAL CO.,LTD. Stock Aurisco Pharmaceutical Co.,Ltd.
-4.11% 1.39B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 664B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.01% 567B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 330B
ABBVIE INC. Stock AbbVie Inc.
+4.23% 286B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.60% 234B
NOVARTIS AG Stock Novartis AG
+4.76% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-10.14% 196B
AMGEN INC. Stock Amgen Inc.
-4.04% 148B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 605116 Stock
  4. Financials Aurisco Pharmaceutical Co.,Ltd.